Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials

Table 2 Quality assessment of the included studies according to Cochrane collaboration’s tool for assessing risk of bias

Included studies	Randomized methods	Blind methods	Allocation concealment	Incomplete outcome data	Selective reporting	Other biases
POLLUX	Low risk	Unclear	Unclear	Low risk	Unclear	Unclear
CASTOR	Low risk	Unclear	Unclear	Low risk	Unclear	Unclear
NCT02252172	Low risk	Unclear	Unclear	Low risk	Unclear	Unclear
ALCYONE	Low risk	High risk	Unclear	Low risk	Unclear	Unclear
ICARIA - MM	Low risk	High risk	Unclear	Low risk	Unclear	Unclear
CASSIOPEIA	Low risk	High risk	Unclear	Low risk	Unclear	Unclear
KEYNOTE-183	Low risk	High risk	Unclear	High risk	Unclear	Unclear
KEYNOTE-185	Low risk	High risk	Unclear	High risk	Unclear	Unclear
NCT01478048	Low risk	High risk	Unclear	Low risk	Unclear	Unclear
ELOQUENT-3	Low risk	Unclear	Unclear	Low risk	Unclear	Unclear
ELOQUENT-2	Low risk	Unclear	Unclear	Low risk	Unclear	Unclear

ISSN: 1471-2407